Circulating hsa-miR-5096 predicts 18F-FDG PET/CT positivity and modulates somatostatin receptor 2 expression: a novel miR-based assay for pancreatic neuroendocrine tumors

Circulating hsa-miR-5096 predicts 18F-FDG PET/CT positivity and modulates somatostatin receptor 2 expression: a novel miR-based assay for pancreatic neuroendocrine tumors

Gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs) are rare diseases encompassing pancreatic (PanNETs) and ileal NETs (SINETs), characterized by heterogeneous somatostatin receptors (SSTRs) expression. Treatments for inoperable GEP-NETs are limited, and SSTR-targeted Peptide Receptor Radionuc...

Full description

Bibliographic Details
Main Authors: Martine Bocchini, Marcella Tazzari, Sara Ravaioli, Filippo Piccinini, Flavia Foca, Michela Tebaldi, Fabio Nicolini, Ilaria Grassi, Stefano Severi, Raffaele Adolfo Calogero, Maddalena Arigoni, Joerg Schrader, Massimiliano Mazza, Giovanni Paganelli
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-05-01
Series:Frontiers in Oncology
Subjects:
pancreatic neuroendocrine tumors
PRRT (peptide receptor radionuclide therapy)
miRNA – microRNA
functional imaging (positron-emission tomography)
SSTR2
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1136331/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2023.1136331/full

Similar Items